Argen X SE Overview
Latest ROE for Argen X SE: 25.29% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow25.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ARGX is 25.29%. That is above the Healthcare sector average of 21.18%. Investors often review this figure alongside Argen X SE's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ARGX currently prints 25.29% for ROE, while the sector average sits near 21.18%. That is roughly 19.4% above the sector mean. Large gaps often invite a closer look at Argen X SE's growth, margins, and balance sheet.
Return on Equity shows how effectively Argen X SE converts resources into returns. At 25.29%, ARGX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ARGX's ROE (25.29%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Argen X SE's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
